Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 22, 2022

Safety and Efficacy of Intrathecal Trastuzumab in HER2-Positive Cancer With Leptomeningeal Metastases



Additional Info

A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics
Neuro-oncology 2022 Aug 10;[EPub Ahead of Print], PU Kumthekar, MJ Avram, AB Lassman, NU Lin, E Lee, SA Grimm, M Schwartz, KL Bell Burdett, RV Lukas, K Dixit, I Perron, H Zhang, WJ Gradishar, EI Pentsova, S Jeyapalan, MD Groves, M Melisko, JJ Raizer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading